Hello everybody, I'm Claudio Certione. I work in Istituto Romagnolo per lo Stilio dei Tumori di Namadori in Meldola, another part of Italy, and I'm really happy to focus about many points that we have reached from ASCO 2024 and DHA 2024. Particularly, my institution is performing a new profiling of our patients, adding a new technique to diagnostic method. We know that for every patient, PET CT is the standard of care. Since four years, we are adding to all the consecutive patients seen as newly diagnosed in relapsed refractory or smoldering meloma, the combination of both techniques, PET CT and full body MRI, three Tesla that we use in order to perform very well in accuracy of diagnostic methods. And we have presented this oral communication at ASCO 2024, the results of these monocentric trials in which we have seen that in 26% of the evaluated patients, the journey can change thanks to the addition of full body MRI to PET CT, and particularly they can change the management because they can in some way prevent the switch to another treatment or the start of a newly diagnosed treatment. And this is the basis to improve this protocol. In my institution, we are doing also a new generation of molecular profiling. We want to detect biomarkers, we want to understand better the biology of this heterogeneous disease, and that's why we are working with the Scan92 panel to all our consecutive patients in order to better understand the biology of the disease and in order to detect which drugs for which patients. This is our ambitious end point of this trial, which will be added to the imaging one presented at ASCO, to metabolomic evaluation and to clinic evaluation. Our real goal is to develop new prognostic scores because we think that this will be the best way to optimize what we have available as a treatment because the therapeutic scenario has revolutionized. We need also to have a new generation diagnostic evaluation for our patients. This is the best way to optimize what we have reached. The next future will mean, I hope, potential target therapy, multiple veloma. I dream that and I dream also based on that of MRD evaluation and we should make MRD democratic for every patient. This is not only something for scientists but is becoming the real end point of response. I dream that MRD negativity, sustained MRD negativity, will help us also to have a potential treatment free admission in patients that have a solid response, a long-term response, and maybe we could also imagine a moment in which they are free from treatment. This is a dream, however, I think that we have seen many revolutionary opportunities in these couple of conferences and this is something that is helping us to run to the cure in multiple meloma. This is the best wish that I give to our patients, to their caregivers and to all meloma researchers that every day fight against this strong disease. Thank you for your attention.
HealthTree • June 24, 2024